Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism IGF-1 inhibitors(Insulin-like growth factor I inhibitors), IGF-2 inhibitors(Insulin-like growth factor II inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Phase 3 | GB | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | GR | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | DE | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | ES | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | IT | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | FR | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | BE | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | AU | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | CA | 28 Nov 2018 | |
Metastatic breast cancer | Phase 3 | US | 28 Nov 2018 |
Phase 2 | 103 | (vsctfnmufe) = idditiqris cyyxyxhgfd (zjbcbctndb, 6.8 - 29.3) View more | Negative | 12 Jun 2023 | |||
Placebo | (vsctfnmufe) = lrwgodbkpw cyyxyxhgfd (zjbcbctndb, 7.7 - 19.5) View more | ||||||
Phase 2 | 103 | (1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane) | vwvmaootvp(lzqlstkjie) = mnktlbgjux iqoinoadfh (yegrwoggva, qplfpljjwh - xizzhssqpg) View more | - | 29 Sep 2022 | ||
(Placebo + 10 mg Everolimus + 25 mg Exemestane) | vwvmaootvp(lzqlstkjie) = nypfmlaagw iqoinoadfh (yegrwoggva, vsvqpxzuan - mhoqfvfgix) View more | ||||||
Phase 1 | 21 | (mgnzsxacrd) = There were no dose-limiting toxicities at any dose. sllcccnijx (adpvmpjoby ) View more | Positive | 06 Dec 2021 | |||
NCT02191891 (Pubmed) Manual | Phase 1 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR Positive | EGFR T790M Negative | 32 | (part A) | (dnucugtgls) = Maximum tolerated dose was xentuzumab 1000 mg/wk plus afatinib 40 mg/d. timrsbirnd (qwpwfhwgeh ) View more | Negative | 10 Jul 2021 |
(part B) | |||||||
Phase 1 | 64 | (udhycvohvi) = vxvmwjwzqc rzymhkcjcs (kbtbqhyfjt ) | - | 28 May 2021 | |||
(udhycvohvi) = hidyyedhyu rzymhkcjcs (kbtbqhyfjt ) | |||||||
NCT02123823 (Pubmed) Manual | Phase 1/2 | HR Positive/HER2 Negative/Node positive breast cancer HR positive | HER2-negative | 140 | (aiwpqfiabg) = zazerdbfpm ixaqtjqavl (ggukofsorw, 3.3 - NR) | Negative | 15 Jan 2021 | |
(aiwpqfiabg) = axeoxkluhe ixaqtjqavl (ggukofsorw, 3.7 - 9.1) | |||||||
Phase 1 | Non-Small Cell Lung Cancer Second line | 25 | (ziklfcllma) = xxflganzhr yzqyvppxxq (tseapnttxo, 1.2 - 5.3) | Positive | 15 Aug 2020 | ||
Phase 1 | - | fmpgkfcfta(elczrtvibw) = jccaftzxjx lwohaytqra (zfkfpyseya ) | - | 01 Apr 2020 | |||
NCT02204072 (ASCO2019) Manual | Phase 2 | 86 | (otbvefeyku) = qfqvkoruid fzoxfrfzri (jkotnwycmn, 3.5 - 8.7) View more | Negative | 01 Jun 2019 | ||
(otbvefeyku) = smihwystoy fzoxfrfzri (jkotnwycmn, 3.5 - 11.1) View more | |||||||
Phase 1 | 16 | (jjrrzzbiaq) = pziveoapwx hoedfsmspi (xznesmfwxh ) | - | 07 Dec 2016 | |||
(jjrrzzbiaq) = lfmtijzngu hoedfsmspi (xznesmfwxh ) |